Medically reviewed by Drugs.com. Last updated on Mar 24, 2022.
Generic name: APREPITANT 130mg in 18mL
Dosage form: injection, emulsion
Prevention of Nausea and Vomiting Associated with HEC and MEC
The recommended dosages in adults of CINVANTI, dexamethasone, and a 5-HT3 antagonist for the prevention of nausea and vomiting associated with administration of HEC or MEC are shown in Table 1, Table 2 and Table 3 respectively. Administer CINVANTI intravenously either by injection over a two (2) minute period or by infusion over a thirty (30) minute period on Day 1, completing the injection or infusion approximately 30 minutes prior to chemotherapy.
|Agent||Day 1||Day 2||Day 3||Day 4|
|CINVANTI||130 mg intravenously||None||None||None|
|Dexamethasone*||12 mg orally||8 mg orally||8 mg orally
|8 mg orally
|5-HT3 antagonist||See selected 5-HT3 antagonist prescribing information for recommended dosage||None||None||None|
|CINVANTI||130 mg intravenously|
|Dexamethasone*||12 mg orally|
|5-HT3 antagonist||See selected 5-HT3 antagonist prescribing information for recommended dosage|
|Agent||Day 1||Day 2||Day 3|
|CINVANTI||100 mg intravenously||None||None|
|Oral Aprepitant||None||80 mg orally||80 mg orally|
|Dexamethasone*||12 mg orally||None||None|
|5-HT3 antagonist||See selected 5-HT3 antagonist prescribing information for recommended dosage||None||None|
Preparation of CINVANTI for Administration
Intravenous Injection over a period of 2 minutes
For intravenous injection over a period of 2 minutes, administer 130 mg of CINVANTI as part of a HEC or MEC regimen or 100 mg as part of a MEC regimen as a single dose on Day 1.
Aseptically withdraw 18 mL for the 130 mg dose or 14 mL for the 100 mg dose from the vial. Do not dilute.
The infusion line should be flushed with normal saline before and after administration of CINVANTI.
Intravenous Infusion over a period of 30 minutes
Table 4 includes preparation instructions for CINVANTI for HEC or MEC as a 130 mg single-dose regimen, and for MEC as a 100 mg single-dose followed by 2 days of oral aprepitant as a 3-day regimen. Differences in preparation for each dose are displayed as bolded text.
|Note: The differences in preparation for each recommended dosage of CINVANTI are displayed in bolded text (see Table 1 for HEC Regimen and Table 2 for MEC Regimen).|
|Step 1||Aseptically withdraw 18 mL for the 130 mg dose or 14 mL for the 100 mg dose from the vial and transfer it into an infusion bag* filled with 100 mL of 0.9% Sodium Chloride Injection, USP or 5% Dextrose for Injection, USP.|
|Step 2||Gently invert the bag 4 to 5 times. Avoid shaking.|
|Step 3||Before administration, inspect the bag for particulate matter and discoloration. Discard the bag if particulate and/or discoloration are observed.|
Caution: Do not mix CINVANTI with solutions for which physical and chemical compatibility have not been established.
In-Use Storage Conditions for CINVANTI in Acceptable Intravenous Diluents
Diluted CINVANTI solution is stable at ambient room temperature for up to 6 hours in 0.9% Sodium Chloride Injection, USP or 12 hours in 5% Dextrose Injection, USP or up to 72 hours if stored under refrigeration in 0.9% Sodium Chloride Injection, USP or in 5% Dextrose Injection, USP.
CINVANTI is compatible with 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP.
Frequently asked questions
More about Cinvanti (aprepitant)
- Side effects
- Drug interactions
- During pregnancy
- Pricing & coupons
- En español
- Drug class: NK1 receptor antagonists
- FDA approval history
- Other brands
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.